Glucagon Receptor Signaling Regulates Energy Metabolism via Hepatic Farnesoid X Receptor and Fibroblast Growth Factor 21

• DOI: 10.2337/db17-1502
• Publication Date: 2018-06-20T13:55:15Z
• Authors: Teayoun Kim; Shelly Nason; Cassie Holleman; Mark Pepin; Landon Wilson; Taylor F. Berryhill; Adam R. Wende; Chad Steele; Martin E. Young; Stephen Barnes; Daniel J. Drucker; Brian Finan; Richard DiMarchi; Diego Perez-Tilve; Matthias Tschöp; Kirk M. Habegger
• Keywords: Male; Mice, Knockout; 0303 health sciences; Receptors, Cytoplasmic and Nuclear; Calorimetry, Indirect; Mitochondria, Liver; Diet, High-Fat; Oxidative Phosphorylation; Fibroblast Growth Factors; Mice, Inbred C57BL; 03 medical and health sciences; Gene Expression Regulation; Liver; Organ Specificity; Receptors, Glucagon; Animals; Anti-Obesity Agents; Obesity; Energy Metabolism; Peptides; Cells, Cultured; Adiposity

Glucagon, an essential regulator of glucose and lipid metabolism, also promotes weight loss, in part through potentiation of fibroblast growth factor 21 (FGF21) secretion. However, FGF21 is only a partial mediator of metabolic actions ensuing from glucagon receptor (GCGR) activation, prompting us to search for additional pathways. Intriguingly, chronic GCGR agonism increases plasma bile acid levels. We hypothesized that GCGR agonism regulates energy metabolism, at least in part, through farnesoid X receptor (FXR). To test this hypothesis, we studied whole-body and liver-specific FXR-knockout (Fxr∆liver) mice. Chronic GCGR agonist (IUB288) administration in diet-induced obese (DIO) Gcgr, Fgf21, and Fxr whole-body or liver-specific knockout (∆liver) mice failed to reduce body weight when compared with wild-type (WT) mice. IUB288 increased energy expenditure and respiration in DIO WT mice, but not Fxr∆liver mice. GCGR agonism increased [14C]palmitate oxidation in hepatocytes isolated from WT mice in a dose-dependent manner, an effect blunted in hepatocytes from Fxr∆liver mice. Our data clearly demonstrate that control of whole-body energy expenditure by GCGR agonism requires intact FXR signaling in the liver. This heretofore-unappreciated aspect of glucagon biology has implications for the use of GCGR agonism in the therapy of metabolic disorders.